Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 29;18(8):1648. doi: 10.3390/ijms18081648

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Apoptotic effect of TRAIL (100 ng/mL) in combination with paclitaxel, cabazitaxel and docetaxel in CSCs and non-CSCs subpopulations within DU145 and PC3 prostate cancer cells. The values represent mean ± SD (n = 6). Within CSCs subpopulation: * p < 0.05, significantly different from the respective control; # p < 0.05, significantly different from TRAIL alone. $ p < 0.05, significantly different from respective taxane alone. Within non-CSCs subpopulation: ** p < 0.05, significantly different from the respective control; ## p < 0.05, significantly different from TRAIL alone. $$ p < 0.05, significantly different from respective taxane alone. (a) Apoptotic effect of TRAIL (100 ng/mL) in combination with paclitaxel, within CSCs and non-CSCs subpopulations in PC3 prostate cancer cells; (b) Apoptotic effect of TRAIL (100 ng/mL) in combination with paclitaxel, within CSCs and non-CSCs subpopulations in DU145 prostate cancer cells; (c) Apoptotic effect of TRAIL (100 ng/mL) in combination with cabazitaxel, within CSCs and non-CSCs subpopulations in PC3 prostate cancer cells; (d) Apoptotic effect of TRAIL (100 ng/mL) in combination with cabazitaxel, within CSCs and non-CSCs subpopulations in DU145 prostate cancer cells; (e) Apoptotic effect of TRAIL (100 ng/mL) in combination with docetaxel, within CSCs and non-CSCs subpopulations in PC3 prostate cancer cells; (f) Apoptotic effect of TRAIL (100 ng/mL) in combination with docetaxel, within CSCs and non-CSCs subpopulations in DU145 prostate cancer cells.

Apoptotic effect of TRAIL (100 ng/mL) in combination with paclitaxel, cabazitaxel and docetaxel in CSCs and non-CSCs subpopulations within DU145 and PC3 prostate cancer cells. The values represent mean ± SD (n = 6). Within CSCs subpopulation: * p < 0.05, significantly different from the respective control; # p < 0.05, significantly different from TRAIL alone. $ p < 0.05, significantly different from respective taxane alone. Within non-CSCs subpopulation: ** p < 0.05, significantly different from the respective control; ## p < 0.05, significantly different from TRAIL alone. $$ p < 0.05, significantly different from respective taxane alone. (a) Apoptotic effect of TRAIL (100 ng/mL) in combination with paclitaxel, within CSCs and non-CSCs subpopulations in PC3 prostate cancer cells; (b) Apoptotic effect of TRAIL (100 ng/mL) in combination with paclitaxel, within CSCs and non-CSCs subpopulations in DU145 prostate cancer cells; (c) Apoptotic effect of TRAIL (100 ng/mL) in combination with cabazitaxel, within CSCs and non-CSCs subpopulations in PC3 prostate cancer cells; (d) Apoptotic effect of TRAIL (100 ng/mL) in combination with cabazitaxel, within CSCs and non-CSCs subpopulations in DU145 prostate cancer cells; (e) Apoptotic effect of TRAIL (100 ng/mL) in combination with docetaxel, within CSCs and non-CSCs subpopulations in PC3 prostate cancer cells; (f) Apoptotic effect of TRAIL (100 ng/mL) in combination with docetaxel, within CSCs and non-CSCs subpopulations in DU145 prostate cancer cells.